PIXIUM VISION SA EO 1,-Share · FR001400JX97 · A3EJJQ (XPAR) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of PIXIUM VISION SA EO 1,-
No Price
Share Float & Liquidity
Free Float56,64 %
Shares Float1,74 M
Shares Outstanding3,08 M
Company Profile for PIXIUM VISION SA EO 1,- Share
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.